Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Amortization of Deferred Charges (2021 - 2025)

Kezar Life Sciences' Amortization of Deferred Charges history spans 5 years, with the latest figure at $37000.0 for Q3 2025.

  • For Q3 2025, Amortization of Deferred Charges fell 42.19% year-over-year to $37000.0; the TTM value through Sep 2025 reached $304000.0, up 20.63%, while the annual FY2024 figure was $259000.0, 10.21% up from the prior year.
  • Amortization of Deferred Charges for Q3 2025 was $37000.0 at Kezar Life Sciences, down from $42000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $159000.0 in Q1 2025 and bottomed at $37000.0 in Q3 2025.
  • The 5-year median for Amortization of Deferred Charges is $59000.0 (2023), against an average of $64687.5.
  • The largest YoY upside for Amortization of Deferred Charges was 148.44% in 2025 against a maximum downside of 42.19% in 2025.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $91000.0 in 2021, then tumbled by 40.66% to $54000.0 in 2022, then rose by 9.26% to $59000.0 in 2023, then grew by 11.86% to $66000.0 in 2024, then tumbled by 43.94% to $37000.0 in 2025.
  • Per Business Quant, the three most recent readings for KZR's Amortization of Deferred Charges are $37000.0 (Q3 2025), $42000.0 (Q2 2025), and $159000.0 (Q1 2025).